FDA launches pilot to boost domestic animal drug manufacturing and reduce supply chain vulnerabilities

The US Food and Drug Administration has introduced a pilot scheme to encourage onshore production of animal drugs, aiming to strengthen supply chain resilience and enhance domestic pharmaceutical capacity.

The US Food and Drug Administration has opened a pilot scheme designed to draw more animal drug manufacturing back onshore, in a move aimed at making veterinary medicine supply chains less vulnerable to disruption.

According to the agency’s Centre for Veterinary Medicine, applications will be given priority consideration when both the finished animal drug and its active ingredient are made in the United States. The FDA said the approach is intended to reduce the risk of shortages and support its broader push to expand domestic pharmaceutical production.

The programme also gives sponsors the option to include a second US-based active ingredient source in an original submission, provided at least one source is domestically manufactured. That could spare companies the delay of filing a post-approval supplement later.

The initiative borrows from FDA programmes already used in human medicines, including prioritisation schemes for generic drug applications and broader efforts to speed facility readiness and manufacturing review.

The agency said it will monitor take-up and may adjust the pilot as it gathers feedback from industry. For animal-health companies, the signal is clear: domestic capacity is becoming a regulatory advantage, not merely a policy objective.